Sun Pharmaceutical Industries Ltd: results and news
Every Sun Pharmaceutical Industries Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: exchange query, credit rating, earnings.
The company said the 30 Oct 2026 news report concerned developments in August 2026 and that it could not attribute the share price move to it or to any particular factor.
The company says the 30 Oct 2026 news report on its Assam plant did not concern a new event, and that it cannot attribute its share price move to the report.
Sun Pharmaceutical Industries reported consolidated total income of ₹16,716.03 crore and net profit of ₹1,995.07 crore for the quarter ended 30 Sep 2026. On a standalone basis, total income was ₹6,222.93 crore and net profit ₹871.29 crore. The company said in a filing on 30 Oct 2026.
Sun Pharmaceutical Industries Limited has told the exchanges that CRISIL Ratings and ICRA have assigned ratings to its proposed non-convertible debenture (NCD) programme and reaffirmed the ratings on its existing facilities. CRISIL has assigned Crisil AAA/Stable to ₹15,000 crore of proposed NCDs and reaffirmed Crisil A1+ on ₹4,000 crore of commercial paper and Crisil AAA/Stable/Crisil A1+ on ₹176 crore of bank facilities. ICRA has assigned [ICRA]AAA (Stable) to the proposed NCDs and reaffirmed [ICRA]A1+ on commercial paper and [ICRA]AAA (Stable)/[ICRA]A1+ on its long-term and short-term limits.